MARTIN, JOEL H.,WANG, LI-HSIEN,STEVENS, SEAN,ALLISON, ERIN M.
申请号：
CA2695199
公开号：
CA2695199C
申请日:
2008.07.31
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
A human antibody or antigen-binding fragment of an antibody that specificallybinds human CD20 and is capableof inducing complement dependent cytotoxicity (CDC), and is capable ofincreasing symptom free survival time between about2-fold to about 9-fold or more, relative to control-treated animals in a mousemodel of human lymphoma. The antibody orantigen--binding fragment thereof is useful in a therapeutic method fortreating a CD20-mediated disease or condition, such as for example,non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus,Crohn's disease, chronic lymphocytic leukemia, andinflammatory diseases.
